Epidemiological data for hepatitis D in Africa
Edouard Tuaillon, Dramane Kania, Emmanuel Gordien, Philippe van de Perre, Pierre Dujols

▶ To cite this version:

Edouard Tuaillon, Dramane Kania, Emmanuel Gordien, Philippe van de Perre, Pierre Dujols. Epidemiological data for hepatitis D in Africa. The Lancet global health, Elsevier, 2018, 6 (1), 10.1016/S2214-109X(17)30463-1. hal-01890197

HAL Id: hal-01890197
https://hal.archives-ouvertes.fr/hal-01890197
Submitted on 6 Jan 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Epidemiological data for hepatitis D in Africa

The systematic review on the seroprevalence of hepatitis D virus in sub-Saharan Africa by Alexander Stockdale and colleagues1 is a key contribution to the epidemiology of hepatitis D virus infection, and highlights the scarcity of reliable data from the African continent. Most of the studies included in this meta-analysis were based on convenience sampling, and less than half of these studies include a confirmation of hepatitis D virus infection by a molecular test. The Article concludes that there is a need for reliable epidemiological data that are representative of the general population, that there are localised clusters of hepatitis D virus endemicity, and that there is a need for reliable hepatitis D virus testing methods.

The first international assessment of external quality control for hepatitis D virus RNA quantification demonstrated the insufficient performances of several assays to detect viruses circulating in Africa (ie, genotypes 1 and 5–8).2 Although new, improved assays have been developed,3 implementation of PCR to detect hepatitis D virus remains challenging in Africa. Collection of dried blood spot (DBS) samples is a promising way to facilitate access to nucleic acid testing. WHO has recently recommended serological and molecular testing on DBS specimens as an alternative to blood samples for the diagnosis of hepatitis B and hepatitis C and for large epidemiological surveillance studies in under-resourced regions and remote areas.4 From our experience, DBS samples can also be used to detect hepatitis D virus antibodies and RNA in samples over 10,000 IU/mL.

In a study supported by the French National Agency for AIDS Research (ANRS 12270), DBS samples collected from more than 15,000 adult volunteers during the 2010 Demographic and Health Survey in Burkina Faso in west Africa were tested for hepatitis D virus infection. Among HBsAg carriers, the seroprevalence estimates of hepatitis D virus were 1.1% (95% CI 0.6–1.6) countrywide, 1.4% (0.7–2.0) in men, and 0.7% (0.1–1.4) in women. Heterogeneous geographical distribution of seroprevalence was observed, with estimates of 5.4% (2.2–8.6) in Cascades and 8.7% (2.5–15.0) in Sud-Ouest regions, suggesting local clusters of endemicity (figure).

These results highlight that DBS specimens collected during Demographic and Health Surveys and having large samples could be useful for estimating the prevalence of diseases, allowing reliable country-wide and regional distribution of prevalence estimates. We suggest that such surveys might provide opportunities to fill the gaps in the knowledge of epidemic hepatitis infections and to guide national and regional infection control programmes.

We declare no competing interests.

Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

*Edouard Tuaillon, Dramane Kania, Emmanuel Gordien, Philippe Van de Perre, Pierre Dujols
et-tuaillon@chu-montpellier.fr
Pathogenesis and Control of Chronic Infections, Inserm U1058, Université de Montpellier, France (ET, PVP, PD); CHU de Montpellier, Montpellier, France (ET, PVP, PD); Laboratoire de Virologie, Centre MURAZ, Bobo-Dioulasso, Burkina Faso (DK); and Laboratoire de Microbiologie Clinique, Centre National de référence des hépatites B, C et Delta, Hôpitaux Universitaires de Paris Seine-Saint-Denis, Université Sorbonne Paris Cité, Paris, France (EG)


Figure: Countrywide prevalence of anti-hepatitis D virus antibodies in Burkina Faso among HBsAg carriers